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Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients
With Premature Atherosclerotic Cardiovascular Disease
Dhruv Mahtta, DO, MBA; David J. Ramsey, PhD; Mahmoud Al Rifai, MD, MPH; Khurram Nasir, MD, MPH; Zainab Samad, MBBS, MHS; David Aguilar, MD; Hani Jneid, MD;
Christie M. Ballantyne, MD; Laura A. Petersen, MD, MPH; Salim S. Virani, MD, PhD

Abstract

Key Points

IMPORTANCE Studies on the use of and adherence to secondary prevention therapies in patients
with premature and extremely premature atherosclerotic cardiovascular disease (ASCVD)

Question Are there differences in the
aspirin use, statin use, and statin
adherence in patients with premature or

are lacking.

extremely premature atherosclerotic

OBJECTIVE To evaluate and compare aspirin use, any statin use, high-intensity statin use, and statin

cardiovascular disease (ASCVD)?

adherence among patients with premature or extremely premature ASCVD compared with patients

Findings In this cross-sectional study of

with nonpremature ASCVD.

1 248 158 US veterans with ischemic
heart disease, peripheral arterial

DESIGN, SETTING, AND PARTICIPANTS This multicenter cross-sectional study used the clinical and

disease, or ischemic cerebrovascular

administrative data sets of the US Department of Veterans Affairs (VA) to identify adult patients with

disease, those with premature or

at least 1 primary care visit in the VA health care system between October 1, 2014, and September

extremely premature ASCVD were

30, 2015. The study cohort comprised patients with ASCVD (ischemic heart disease, peripheral

statistically significantly less likely to

arterial disease, or ischemic cerebrovascular disease) who were enrolled in the Veterans With

receive aspirin or any statin and to

Premature Atherosclerosis (VITAL) registry. Patients with missing data for date of birth or sex and

adhere to statin therapy.

those with limited life expectancy were excluded. Data were analyzed from November 1, 2019, to
January 1, 2020.

Meaning Results of this study suggest
that patients with premature or
extremely premature ASCVD have a

EXPOSURES Premature (the first ASCVD event occurred at age <55 years for men and age <65 years
for women) vs nonpremature (the first ASCVD event occurred at age ⱖ55 years for men or age ⱖ65
years for women) ASCVD and extremely premature (the first ASCVD event occurred at age <40
years) vs nonpremature ASCVD.

greater accrued lifetime risk of adverse
cardiovascular events, which warrant
directed initiatives that can mitigate the
disparities in medication use and
adherence.

MAIN OUTCOMES AND MEASURES The primary outcomes were aspirin use, any statin use, highintensity statin use, and statin adherence (measured by proportion of days covered [PDC] ⱖ0.8).
RESULTS Of the 1 248 158 patients identified, 135 703 (10.9%) had premature ASCVD (mean [SD]

Author affiliations and article information are
listed at the end of this article.

age, 49.6 [5.8] years; 116 739 men [86.0%]), 1 112 455 (89.1%) had nonpremature ASCVD (mean [SD]
age, 69.6 [8.9] years; 1 104 318 men [99.3%]), and 7716 (0.6%) had extremely premature ASCVD
(mean [SD] age, 34.2 [4.3] years; 6576 men [85.2%]). Patients with premature ASCVD vs those with
nonpremature ASCVD had lower rates of aspirin use (96 468 [71.1%] vs 860 726 [77.4%]; P < .001)
and any statin use (98 908 [72.9%] vs 894 931 [80.5%]; P < .001); had a statin PDC of 0.8 or higher
(57 306 [57.9%] vs 644 357 [72.0%]; P < .001); and a higher rate of high-intensity statin use (49 354
[36.4%] vs 332 820 [29.9%]; P < .001). Similarly, patients with extremely premature ASCVD were
less likely to use aspirin (odds ratio [OR], 0.27; 95% CI, 0.26-0.29), any statin (OR, 0.25; 95% CI,
0.24-0.27), or high-intensity statin (OR, 0.78; 95% CI, 0.74-0.82) and to be statin adherent (OR,
0.44; 95% CI, 0.41-0.47).
(continued)
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Abstract (continued)

CONCLUSIONS AND RELEVANCE In this study, patients with premature or extremely premature
ASCVD appeared to be less likely to use aspirin or statins and to adhere to statin therapy. This finding
warrants further investigation into premature ASCVD and initiatives, including clinician and patient
education, to better understand and mitigate the disparities in medication use and adherence.
JAMA Network Open. 2020;3(8):e2011051. doi:10.1001/jamanetworkopen.2020.11051

Introduction
Substantial advancements in prevention of atherosclerotic cardiovascular disease (ASCVD) have led
to substantial improvements in adverse cardiovascular events and associated mortality.1-3 Despite
the improvements, the incidence of ASCVD has increased in younger patients.4 This trend is
prevalent across all 3 domains of ASCVD: ischemic heart disease (IHD), ischemic cerebrovascular
disease (ICVD), and peripheral arterial disease (PAD).5-10 Furthermore, patients with premature
ASCVD experience similar rates of all-cause and cardiovascular mortality compared with
older adults.11-14
The use of aspirin and high-intensity statin for secondary prevention of ASCVD is well
established and endorsed by multisociety guidelines.15-18 A strong association between
nonadherence with these secondary prevention measures and increased cardiovascular mortality
has also been well demonstrated.19,20 Whether the similarity in rates of cardiovascular mortality
between older patients with ASCVD and younger patients with premature ASCVD is attributable to
less aggressive implementation of and adherence with secondary prevention strategies among
younger adults remains unknown because it has not been studied. Although a previous investigation
evaluated statin use in younger patients, the study was limited to 1 domain of ASCVD (IHD).21 Hence,
a thorough assessment of statin use across the entire spectrum of patients with premature ASCVD
is unavailable. Data on statin adherence and the use of aspirin in this population are also scarce.
The primary objective of this cross-sectional study was to evaluate aspirin use, statin use, and
statin adherence in patients with premature ASCVD vs in patients with nonpremature ASCVD. We
also investigated similar outcomes among patients with extremely premature ASCVD because these
individuals are at risk for a higher accrued lifetime morbidity and health care financial burden.

Methods
The study protocol was approved, and informed consent was waived by the institutional review
board at Baylor College of Medicine. The data obtained for this study did not involve interaction with
any patients and did not include any individually identifiable information. We followed the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline.22
Using the US Department of Veterans Affairs (VA) clinical and administrative data sets, we
identified 1 248 158 patients with ASCVD aged 18 years or older who received primary care services
between October 1, 2014, and September 30, 2015 (VA fiscal year 2015), across the 130 main VA
facilities and their associated community-based outpatient clinics in the US. The most recent primary
care visit during fiscal year 2015 was used as the index primary care physician (PCP) visit and as an
anchor for the present analyses. Additional details regarding this cohort have been described
previously.23 The presence of ASCVD was defined as a history of IHD, ICVD, or PAD, which was
ascertained from recorded International Classification of Diseases, Ninth Revision, Clinical
Modification diagnosis and procedural codes or Current Procedural Terminology codes.24,25 Based on
a manual medical record review of 200 patients, the algorithm we used computed a 95% positive
predictive value for correct identification of ASCVD.26,27
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We analyzed patients enrolled in the nationwide Veterans With Premature Atherosclerosis
(VITAL) registry, which was created from the large cohort of adults with ASCVD.28 In accordance with
national cardiovascular guidelines, premature ASCVD was defined as the first ASCVD event occurring
before age 55 years for men and before age 65 years for women.29 These adults with premature
ASCVD were included in the VITAL registry. Nonpremature ASCVD was defined as the first ASCVD
event occurring at age 55 years or older for men or age 65 years or older for women. Furthermore,
extremely premature ASCVD was defined as the first ASCVD event occurring before age 40 years.
Patients with nonpremature and extremely premature ASCVD were also included in this study. Aside
from patients with missing date of birth or sex data, patients with limited life expectancy, as indicated
by a history of metastatic cancer in the past 5 years or receipt of hospice care in the past 12 months,
were excluded from the analyses.30
Clinical data sources in the VA system were used to identify patient age, sex, race/ethnicity, and
body mass index (calculated as weight in kilograms divided by height in meters squared). Medical
history of hypertension, diabetes, myocardial infarction, IHD, ICVD, and PAD was ascertained from
International Classification of Diseases, Ninth Revision, Clinical Modification and Current Procedural
Terminology codes. The VA data sets included baseline levels of low-density lipoprotein cholesterol,
non–high-density lipoprotein cholesterol, triglycerides, lipoprotein A, and apolipoprotein B. The
Diagnosis Cost Group (DCG) relative risk score, a well-established and validated surrogate marker of
the overall illness burden, was also calculated.31,32 A DCG relative risk score of 1 signified an average
illness burden; a score above 1, a higher-than-average illness burden; and a score below 1, a lowerthan-average illness burden. We also identified various facility-level and clinician-level variables,
including receipt of care from a physician vs an advanced practice practitioner (nurse practitioner or
physician assistant), a teaching vs nonteaching facility, and an urban vs a rural facility; median
number of PCP visits in the 12 months before the index PCP visit; and percentage of patients
receiving cardiological and PCP services in the 12 months before the index PCP visit. We ascertained
the median number of days from the first ASCVD event to the index PCP visit, nonaspirin antiplatelet
use, and anticoagulant use among this cohort.
The primary outcomes in this study were aspirin use, any statin use, high-intensity statin use,
and statin adherence, which were ascertained from the VA pharmacy data. The term use referred to
an existing prescription for the said medication within 100 days before or 14 days after the index
PCP visit. The prescribed statin drugs included atorvastatin, rosuvastatin, pravastatin, fluvastatin,
lovastatin, simvastatin, and pitavastatin. In accordance with the national cholesterol guidelines,33
high-intensity statin was defined as atorvastatin, 40 mg or more, or rosuvastatin, 20 mg or more. We
included both aspirin and statin therapy that were prescribed outside the VA health care system if
proper notations were made in the VA primary care encounter. Adherence to statin therapy was
assessed by the proportion of days covered (PDC), a well-established and validated method that has
been documented previously.32,34 The PDC was calculated by dividing the number of days with
(covered by) a certain statin prescription refill by the total number of days within that period.35 The
PDC calculations accounted for changes in statin doses or type of statin and early refills. If statin dose
was changed, we assumed pill splitting or doubling to match the new dose from the previous supply.
If the statin type was changed, we assumed the remaining supply of the previous statin was
discarded in favor of the new statin. We also accounted for stockpiling by assuming that early refills
were not consumed until the previous supply was finished. Based on data from previous studies on
medication adherence,36 patients were deemed to be adherent to statin therapy if the PDC was 0.8
or higher. We measured the PDC both as a categorical variable (ⱖ0.8 or <0.8) and as a continuous
variable. The term adherence referred to the filling or refilling of prescriptions by the patients.

Statistical Analysis
We assessed the distribution of various patient-, facility-, and clinician-level variables across patients
with premature and nonpremature ASCVD. Categorical variables were analyzed with a χ2 test, and
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continuous variables were analyzed with an unpaired, 2-tailed t test. Two-sided P < .05 was used to
indicate statistical significance.
Use of aspirin, any statin, and high-intensity statin and statin adherence were evaluated across
patients with premature ASCVD and nonpremature ASCVD. Subsequently, we created multivariable
hierarchical logistic and linear regression models to study the association between premature ASCVD
and aspirin use, any statin use, high-intensity statin use, and statin adherence. Identical analytical
methods were used to study patients with extremely premature ASCVD. The referent category
included patients with nonpremature ASCVD.
All analyses were adjusted for sex, race/ethnicity, type of ASCVD, history of obesity,
hypertension, diabetes, DCG relative risk score, median number of days from first ASCVD event to
index PCP visit, and facility- and clinician-level covariates. The regression models for aspirin use were
adjusted for nonaspirin antiplatelet use and anticoagulant use. Generalized linear latent and mixed
models adjusted the regression models for facility-level clustering of patients. Analyses were
performed with SAS, version 9.1.3 (SAS Institute Inc) and Stata, version 14 (StataCorp LLC) from
November 1, 2019, to January 1, 2020.

Results
A total of 1 248 158 patients with ASCVD were identified after excluding patients with missing date of
birth or sex data (n = 95), with limited life expectancy (n = 28 316), or with missing DCG relative risk
score variable (n = 129). After age-based exclusion was applied, a total of 135 703 patients (10.9%)
with premature ASCVD (mean [SD] age, 49.6 [5.8] years; 116 739 men [86.0%]) were included in the
VITAL registry (Table 1). Accordingly, 1 112 455 patients (89.1%) were identified as having
nonpremature ASCVD (mean [SD] age, 69.6 [8.9] years; 1 104 318 men [99.3%]).
The premature ASCVD group compared with the nonpremature ASCVD group comprised a
higher proportion of female (18 964 [14.0%] vs 8137 [0.7%]), Asian (967 [0.7%] vs 4898 [0.4%]),
and Black patients (34 008 [25.1%] vs 110 516 [9.9%]) and a lower proportion of White patients
(90 835 [66.9%] vs 891 800 [80.2%]). A higher proportion of patients with premature ASCVD vs
those with nonpremature ASCVD had a body mass index of 30 or higher (75 519 of 135 703 [55.7%]
vs 442 891 of 1 112 455 [39.8%]), whereas a lower proportion had a history of diabetes (65 263
[48.1%] vs 565 444 [50.8%]) and hypertension (127 519 [94.0%] vs 1 064 670 [95.7%]). The
prevalence of IHD (105 659 [77.9%] vs 884 063 [79.5%]) and PAD (16 890 [12.5%] vs 178 859
[16.1%]) was lower and the prevalence of myocardial infarction was higher (64 371 [47.4%] vs
278 025 [25.0%]) among patients with premature ASCVD than in those with nonpremature ASCVD.
Patients with premature ASCVD had higher levels of mean (SD) total cholesterol (238.89 [63.65]
mg/dL vs 214.20 [51.62] mg/dL), low-density lipoprotein cholesterol (150.84 [44.04] mg/dL vs
134.02 [40.46] mg/dL [to convert cholesterol levels to millimoles per liter, multiply by 0.0259]), and
non–high-density lipoprotein cholesterol (193.16 [61.45] mg/dL vs 168.73 [50.52] mg/dL) (P < .001
for all comparisons).
Table 2 shows that a statistically significantly lower proportion of patients with premature
ASCVD vs nonpremature ASCVD received aspirin therapy (96 468 [71.1%] vs 860 726 [77.4%];
P < .001) and any statin therapy (98 908 [72.9%] vs 894 931 [80.5%]; P < .001). However, a higher
number of patients with premature ASCVD received high-intensity statin (49 354 [36.4%] vs
332 820 [29.9%]; P < .001). Patients with premature ASCVD had a statistically significantly lower
mean (SD) PDC (0.71 [0.32] vs 0.80 [0.29]; adjusted odds ratio [OR], −0.083 [95% CI, −0.084 to
−0.081]; P < .001) and a lower proportion of patients with PDC of 0.8 or higher (57 306 [57.9%] vs
644 357 [72.0%]; P < .001). In fully adjusted regression models, premature ASCVD was associated
with a lower likelihood of aspirin use (OR, 0.69; 95% CI, 0.68-0.70), any statin use (OR, 0.70; 95%
CI, 0.69-0.71), and statin adherence (OR, 0.56; 95% CI, 0.55-0.57) (Figure). In contrast, premature
ASCVD was independently associated with a 37% higher likelihood of high-intensity statin use (OR,
1.37; 95% CI, 1.35-1.39).
JAMA Network Open. 2020;3(8):e2011051. doi:10.1001/jamanetworkopen.2020.11051 (Reprinted)
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A total of 7716 patients (0.6%) with extremely premature ASCVD (mean [SD] age, 34.2 [4.3]
years; 6576 men [85.2%] and 1140 women [14.8%]) were identified (Table 3). Compared with
patients with nonpremature ASCVD, patients with extremely premature ASCVD had a higher
proportion of female (1140 [14.8%] vs 8137 [0.7%]), Asian (111 [1.4%] vs 4898 [0.4%]), and Black
patients (1859 [24.1%] vs 110 516 [9.9%]) and a lower proportion of White patients (5171 [67.0%] vs
891 800 [80.2%]). A statistically significantly higher proportion of patients with extremely
premature ASCVD had a body mass index of 30 or higher (75 519 of 135 703 [55.7%] vs 442 891 of
1 112 455 [39.8%]) and had a history of myocardial infarction (3534 [45.8%] vs 278 025 [25.0%]).
However, the prevalence of hypertension (6334 [82.1%] vs 1 064 670 [95.7%]) and diabetes (1960
[25.4%] vs 565 444 [50.8%]) was lower. A higher prevalence of ICVD (2499 [32.4%] vs 311 168
[28.0%]) and a lower prevalence of IHD (5180 [67.1%] vs 884 063 [79.5%]) and PAD (587 [7.6%] vs
178 859 [16.1%]) were observed among patients with extremely premature ASCVD. In addition, these
patients were observed to have higher mean (SD) levels of total cholesterol (229.51 [64.36] mg/dL
vs 214.20 [51.62] mg/dL), low-density lipoprotein cholesterol (145.67 [46.87] mg/dL vs 134.02

Table 1. Baseline Characteristics of Patients With or Without Premature ASCVD
No. (%)
Patients with premature
ASCVD (n = 135 703)a

Patients with nonpremature
ASCVD (n = 1 112 455)b

Age, mean (SD), y

49.6 (5.8)

69.6 (8.9)

<.001

Male sex

116 739 (86.0)

1 104 318 (99.3)

<.001

Characteristic

P value

Demographic

Race/ethnicity
Asian

967 (0.7)

4898 (0.4)

<.001

Black

34 008 (25.1)

110 516 (9.9)

<.001

White

90 835 (66.9)

891 800 (80.2)

<.001

BMI ≥30

75 519 (55.7)

442 891 (39.8)

<.001

Hypertension

127 519 (94.0)

1 064 670 (95.7)

<.001

Diabetes

65 263 (48.1)

565 444 (50.8)

<.001

IHD

105 659 (77.9)

884 063 (79.5)

<.001

Myocardial infarction

64 371 (47.4)

278 025 (25.0)

<.001

ICVD

38 275 (28.2)

311 168 (27.9)

.07
<.001

Medical history

PAD

16 890 (12.5)

178 859 (16.1)

LDL-C, mean (SD), mg/dL

150.84 (44.04)

134.02 (40.46)

<.001

Non–HDL-C, mean (SD), mg/dL

193.16 (61.45)

168.73 (50.52)

<.001

Total cholesterol, mean (SD), mg/dL

238.89 (63.65)

214.20 (51.62)

<.001

Lp(a), mean (SD), mg/dL

40.49 (58.32)

31.42 (42.71)

<.001

apoB, mean (SD), mg/dL

106.26 (37.09)

94.02 (31.39)

<.001

1658 (1001-3002)

1594 (1069-1780)

<.001

Overall health status and health care use
No. of days from ASCVD event to index
PCP visit, median (IQR)
DCG relative risk score, mean (SD)

2.18 (2.59)

1.54 (2.13)

<.001

Nonaspirin antiplatelet use

29 948 (22.1)

268 270 (24.1)

<.001

Anticoagulant use

14 196 (10.5)

188 459 (16.9)

<.001

Facility- and clinician-level characteristics
Receiving care at teaching facility

63 360 (46.7)

421 523 (37.9)

<.001

PCP

105 255 (77.6)

855 134 (76.9)

<.001

Receiving care at rural facility

9643 (7.1)

86 047 (7.7)

<.001

Patients with a PCP visit in the
12 mo before index PCP visit

128 781 (94.9)

1 018 122 (91.5)

<.001

Patients with a cardiology visit in the
12 mo before index PCP visit

36 750 (27.1)

228 154 (20.5)

<.001

No. of PCP visits in the 12 mo before
index PCP visit, median (IQR)

4 (2-7)

3 (1-6)

<.001
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Abbreviations: apoB, apolipoprotein B; ASCVD,
atherosclerotic cardiovascular disease; BMI, body mass
index (calculated as weight in kilograms divided by
height in meters squared); DCG, Diagnostic Cost
Group; HDL-C, high-density lipoprotein cholesterol;
ICVD, ischemic cerebrovascular disease; IHD, ischemic
heart disease; IQR, interquartile range; LDL-C,
low-density lipoprotein cholesterol; Lp(a), lipoprotein
A; PAD, peripheral arterial disease; PCP, primary care
physician.
SI conversion factors: To convert apoB to grams per
liter, multiply by 0.01; HDL-C, LDL-C, and total
cholesterol to millimoles per liter, multiply by 0.0259;
and Lp(a) to milligrams per liter, multiply by 0.1.
a

Patients with premature ASCVD were those who
experienced their first ASCVD event before age 55
years for men and before age 65 years for women.

b

Patients with nonpremature ASCVD were those who
experienced their first ASCVD event at age 55 years
or older for men and age 65 years or older
for women.
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[40.46] mg/dL), and non–high-density lipoprotein cholesterol (184.88 [63.54] mg/dL vs 168.73
[50.52] mg/dL) (P < .001 for all comparisons).
A lower proportion of patients with extremely premature ASCVD vs those with nonpremature
ASCVD received aspirin (3668 [47.5%] vs 860 726 [77.4%]; P < .001), any statin (3523 [45.7%] vs
894 931 [80.5%]; P < .001), and high-intensity statin (1755 [22.7%] vs 332 820 [29.9%]; P < .001)
(Table 4). The mean (SD) statin PDC (0.64 [0.36] vs 0.80 [0.29]; adjusted OR, −0.15 [95% CI, −0.16
to −0.14]; P < .001) and proportion of patients with statin PDC of 0.8 or higher (1830 [51.9%] vs
644 357 [72.0%]; P < .001) were lower among patients with extremely premature ASCVD. Extremely
premature ASCVD was independently associated with lower odds of aspirin use (OR, 0.27; 95% CI,
0.26-0.29), any statin use (OR, 0.25; 95% CI, 0.24-0.27), and high-intensity statin use (OR, 0.78;
95% CI, 0.74-0.82) (Figure). The presence of extremely premature ASCVD was also associated with
a 56% lower likelihood of statin adherence (OR, 0.44; 95% CI, 0.41-0.47).

Discussion
This study demonstrated that patients with premature ASCVD or extremely premature ASCVD were
less likely to receive aspirin and any statin therapy than patients with nonpremature ASCVD. Patients
with premature ASCVD were more likely to receive guideline-concordant high-intensity statin,
whereas those with extremely premature ASCVD were less likely to receive this medication.
Furthermore, this study showed that all patients, regardless of their age of ASCVD onset, had
suboptimal use of these secondary prevention medications. Presence of premature or extremely
premature ASCVD was independently associated with lower statin adherence. Such differences
between groups were evident despite patients with premature or extremely premature ASCVD
having a higher frequency of outpatient encounters with PCPs and cardiovascular specialists than
patients with nonpremature ASCVD.
These results present evidence of the existing knowledge gap regarding aspirin and statin use
for secondary prevention among patients with premature ASCVD. The rationale behind the observed
disparities in prescription patterns is likely multifactorial. Although accurate, the prevailing emphasis

Table 2. Aspirin Use, Statin Use, and Statin Adherence Among Patients With Premature ASCVD
No. (%)
Variable

Patients with premature
ASCVD (n = 135 703)a

Patients with nonpremature
ASCVD (n = 1 112 455)b

Adjusted OR
or β coefficient (95% CI)c

P value

Aspirin used

96 468 (71.1)

860 726 (77.4)

0.69 (0.68 to 0.70)d

<.001

Any

98 908 (72.9)

894 931 (80.5)

0.70 (0.69 to 0.71)c

<.001

High-intensity

49 354 (36.4)

332 820 (29.9)

1.37 (1.35 to 1.39)c

<.001

≥0.8

57 306 (57.9)

644 357 (72.0)

0.56 (0.55 to 0.57)c

<.001

Mean (SD)

0.71 (0.32)

0.80 (0.29)

−0.083 (−0.084 to −0.081)

<.001

Statin use

Statin PDC

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; OR, odds ratio; PDC, proportion of days covered.
a

Patients with premature ASCVD were those who experienced their first ASCVD event before age 55 years for men and
before age 65 years for women.

b

Patients with nonpremature ASCVD were those who experienced their first ASCVD event at age 55 years or older for men
and age 65 years or older for women.

c

Adjusted for sex, race/ethnicity, obesity (body mass index ⱖ30 [calculated as weight in kilograms divided by height in
meters squared]), hypertension, diabetes, type of ASCVD (ischemic heart disease vs peripheral arterial disease vs
ischemic cerebrovascular disease), clinician type (physician vs advanced practice practitioner), teaching vs nonteaching
facility, urban vs rural facility, number of cardiology visits 12 months before index primary care physician (PCP) visit,
median number of PCP visits 12 months before index PCP visit, median number of days from first ASCVD event to the
index PCP visit, and Diagnostic Cost Group relative risk score.

d

Regression model for aspirin use was adjusted for nonaspirin platelet use and anticoagulant use in addition to all of the
aforementioned covariates.
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on older age as a leading risk factor of ASCVD37-39 may create the misperception that younger age has
protective properties against ASCVD. Furthermore, as observed in this study, the prevalence of
metabolic risk factors, such as hypertension and diabetes, was often lower among patients with
premature or extremely premature ASCVD. Therefore, it may be hypothesized that in such patients,
nontraditional and nonmetabolic risk factors (eg, hereditary thrombophilia, inflammatory disorders)
may instead be more prevalent.40,41 The treatment of nontraditional and nonmetabolic conditions
may supersede the secondary prevention of ASCVD. In patients with premature ASCVD, the
occurrence of the index ASCVD event at a younger age may be incorrectly perceived as an isolated
episode rather than as the true risk for recurrent adverse cardiovascular events.
Therapeutic inertia, which is defined as the lack of initiation or intensification of clinically
indicated treatment,42,43 may also be an important factor in these observed differences. The
prevalence of therapeutic inertia in statin initiation may be high among patients with premature or
extremely premature ASCVD despite their less favorable baseline lipid profiles. However, the
discordance observed in high-intensity statin use between patients with premature ASCVD and
those with extremely premature ASCVD may indicate a higher prevalence of therapeutic inertia in
statin intensification among patients with extremely premature ASCVD (age of ASCVD onset, 18-39
years) than among patients with premature ASCVD (age of ASCVD onset, 40-54 years for men and
40-64 years for women). Patients with extremely premature ASCVD may experience lower rates of
statin therapy intensification because of preconceived notions that these patients do not have as
high a risk or do not need high doses at a young age. Such patient-level or clinician-level
misconceptions may impede statin intensification among patients with extremely premature ASCVD.

Figure. Rates of Use and Adherence With Statin and Aspirin Therapy Among Patients With Premature
and Extremely Premature Atherosclerotic Cardiovascular Disease (ASCVD)
A Patients with premature and nonpremature ASCVD
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odds of medication use or medication adherence
among patients with either premature ASCVD or
extremely premature ASCVD compared with patients
with nonpremature ASCVD. The true OR has a 95%
certainty of falling between the specified CI range. PDC
indicates the proportion of days covered.
a

Aspirin use regression models were adjusted for
nonaspirin antiplatelet use and anticoagulant use in
addition to sex, race/ethnicity, ischemic heart disease
(IHD), obesity (body mass index [BMI] ⱖ30
[calculated as weight in kilograms divided by height
in meters squared]), hypertension, diabetes, clinician
type (physician vs advanced practice practitioner
[APP]), teaching vs nonteaching facility, urban vs
rural facility, number of cardiology visits 12 months
before the index primary care physician (PCP) visit,
median number of PCP visits 12 months before the
index PCP visit, median number of days from first
ASCVD event to the index PCP visit, and Diagnostic
Cost Group (DCG) relative risk score (marker of the
overall illness burden of the patient).

b

Adjusted for sex, race/ethnicity, IHD, obesity (BMI
ⱖ30), hypertension, diabetes, clinician type
(physician vs APP), teaching vs nonteaching facility,
urban vs rural facility, number of cardiology visits 12
months before the index PCP visit, median number
of PCP visits 12 months before the index PCP visit,
median number of days from first ASCVD event to
the index PCP visit, and DCG relative risk score.
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The presence of premature or extremely premature ASCVD was also associated with lower
statin adherence. This finding is consistent with the finding in a recent investigation that individuals
younger than 55 years were less likely to be statin adherent after a myocardial infarction.44 Younger
patients with premature or extremely premature ASCVD may exhibit unrealistic optimism bias45,46
and lack the necessary understanding of their disease process to foster optimal statin adherence.
Similarly, an overall higher functional status after the index ASCVD event may be misinterpreted by
patients as indicating their reduced need for statin therapy. Although clinical evidence of statinassociated adverse effects based on patient age is lacking,47 the perceived statin-associated adverse
effects among the premature ASCVD population may be another factor in statin discontinuation and
lower adherence rates. As previously reported, social determinants, such as health literacy and social
support, may be associated with medication adherence.48 Hence, in the present study, the
suboptimal adherence observed among patients with premature or extremely premature ASCVD
may be attributed in part to socioeconomic factors. Statin misinformation or misconceptions
because of a greater reliance on social media–based or non–clinician-based resources and a

Table 3. Baseline Characteristics of Patients With or Without Extremely Premature ASCVD
No. (%)
Patients with extremely
premature ASCVD (n = 7716)a

Patients with nonpremature
ASCVD (n = 1 112 455)b

Age, mean (SD), y

34.2 (4.3)

69.6 (8.9)

<.001

Male sex

6576 (85.2)

1 104 318 (99.3)

<.001

Asian

111 (1.4)

4898 (0.4)

<.001

Black

1859 (24.1)

110 516 (9.9)

<.001

White

5171 (67.0)

891 800 (80.2)

<.001

Characteristic

P value

Demographic

Race/ethnicity

Medical history
BMI ≥30

4407 (57.3)

442 891 (39.9)

<.001

Hypertension

6334 (82.1)

1 064 670 (95.7)

<.001

Diabetes

1960 (25.4)

565 444 (50.8)

<.001

IHD

5180 (67.1)

884 063 (79.5)

<.001

Myocardial infarction

3534 (45.8)

278 025 (25.0)

<.001

ICVD

2499 (32.4)

311 168 (28.0)

<.001

PAD

587 (7.6)

178 859 (16.1)

<.001

LDL-C, mean (SD), mg/dL

145.67 (46.87)

134.02 (40.46)

<.001

Non–HDL-C, mean (SD), mg/dL

184.88 (63.54)

168.73 (50.52)

<.001

Total cholesterol, mean (SD), mg/dL

229.51 (64.36)

214.20 (51.62)

<.001

Lp(a), mean (SD), mg/dL

43.34 (42.73)

31.42 (42.71)

.15

apoB, mean (SD), mg/dL

122.45 (33.17)

94.02 (31.39)

<.001

1395 (668-2099)

1594 (1069-1780)

<.001

Overall health status and health care use
No. of days from ASCVD event to index
PCP visit, median (IQR)
DCG relative risk score, mean (SD)

1.95 (2.38)

1.54 (2.13)

<.001

Nonaspirin antiplatelet use

1037 (13.4)

268 270 (24.1)

<.001

Anticoagulant use

754 (9.8)

188 459 (16.9)

<.001

Facility- and clinician-level characteristics
Receiving care at teaching facility

3701 (48.0)

421 523 (37.9)

<.001

PCP

5866 (76.0)

855 134 (76.9)

.08

Receiving care at rural facility

499 (6.5)

86 047 (7.7)

<.001

Patients with a PCP visit in the
12 mo before index PCP visit

7155 (92.7)

1 018 122 (91.5)

<.001

Patients with a cardiology visit in the
12 mo before index PCP visit

1671 (21.7)

228 154 (20.5)

.01

No. of PCP visits in the 12 mo before
index PCP visit, median (IQR)

4 (2-6)

3 (1-6)

<.001

JAMA Network Open. 2020;3(8):e2011051. doi:10.1001/jamanetworkopen.2020.11051 (Reprinted)

Downloaded From: https://jamanetwork.com/ by a Aga Khan University User on 12/01/2020
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atherosclerotic cardiovascular disease; BMI, body mass
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a

Patients with extremely premature ASCVD were
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b

Patients with nonpremature ASCVD were those who
experienced their first ASCVD event at age 55 years
or older for men and age 65 years or older
for women.
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comparative lack of experience in long-term medication management49 may contribute to lower
rates of statin adherence in patients, especially in those with premature ASCVD.
To our knowledge, this study was the first to assess the nationwide disparities in aspirin use,
statin use, and statin adherence among US veterans with premature or extremely premature ASCVD.
The findings revealed the extent of underuse of and suboptimal adherence to secondary prevention
medications in this younger but at-risk population despite adequate clinical encounters with PCPs
and cardiovascular specialists. Suboptimal secondary preventive measures in patients with
premature ASCVD may be associated with a higher accrued lifetime morbidity risk and financial
burden on the health care system. Hence, it is imperative for investigators and health care policy
advisors to recognize the presence and implications of the disparities in medication use and
adherence. Future efforts are needed to provide clinician and patient education to discredit
misperceptions, conduct qualitative and outcomes research into premature ASCVD, and implement
research findings. In addition, evidence-based strategies, such as motivational interviewing and the
Screening, Brief Intervention and Referral to Treatment approach, may be adopted by clinicians to
partially overcome some of the socioeconomic barriers to medication use and adherence.

Limitations
This study has some limitations. Because of the inherent constraints of clinical data sets and the
observational design of the study, we were unable to ascertain and adjust for additional confounders,
such as health literacy of patients, the presence of polypharmacy, and the presence of statinassociated adverse effects or aspirin allergy. We were unable to integrate data from non-VA
pharmacies to identify additional medication filled outside of the VA system, including over-thecounter aspirin use. Although the VA health care system serves a preponderance of older patients
with nonpremature ASCVD, the number of younger and female patients with premature ASCVD
included in the VITAL registry remained substantially large given the national scope of the data set.
The generalizability of the findings to other non-VA facilities may be imperfect.

Table 4. Aspirin Use, Statin Use, and Statin Adherence Among Patients With Extremely Premature
Atherosclerotic Cardiovascular Disease
No. (%)

Variable

Patients with
extremely premature
ASCVD (n = 7716)a

Patients with
nonpremature
ASCVD (n = 1 112 455)b

Adjusted OR/β coefficient
(95% CI)c

P value

Aspirin used

3668 (47.5)

860 726 (77.4)

0.27 (0.26 to 0.29)d

<.001

Statin use
Any

3523 (45.7)

894 931 (80.5)

0.25 (0.24 to 0.27)c

<.001

High-intensity

1755 (22.7)

332 820 (29.9)

0.78 (0.74 to 0.82)c

<.001

≥0.8

1830 (51.9)

644 357 (72.0)

0.44 (0.41 to 0.47)c

<.001

Mean (SD)

0.64 (0.36)

0.80 (0.29)

−0.15 (−0.16 to −0.14)

<.001

Statin PDC

Abbreviations: ASCVD, atherosclerotic cardiovascular disease; OR, odds ratio; PDC, proportion of days covered.
a

Patients with extremely premature ASCVD were those who experienced their first ASCVD event before age 40 years.

b

Patients with nonpremature ASCVD were those who experienced their first ASCVD event at age 55 years or older for men
and age 65 years or older for women.

c

Adjusted for sex, race/ethnicity, obesity (body mass index ⱖ30 [calculated as weight in kilograms divided by height in
meters squared]), hypertension, diabetes, type of ASCVD (ischemic heart disease vs peripheral arterial disease vs
ischemic cerebrovascular disease), clinician type (physician vs advanced practice practitioner), teaching vs nonteaching
facility, urban vs rural facility, number of cardiology visits 12 months before index primary care physician (PCP) visit,
median number of PCP visits 12 months before index PCP visit, median number of days from first ASCVD event to the
index PCP visit, and Diagnostic Cost Group relative risk score.

d

Regression model for aspirin use was adjusted for nonaspirin platelet use and anticoagulant use in addition to all of the
aforementioned covariates.
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Conclusions
In this cross-sectional study, the presence of premature ASCVD appeared to be associated with a
lower likelihood of aspirin use, any statin use, and statin adherence but a higher likelihood of highintensity statin use in contrast to nonpremature ASCVD. Independent associations were observed
between the presence of extremely premature ASCVD and lower odds of aspirin use, any statin use,
high-intensity statin use, and statin adherence. Despite guideline recommendations, secondary
prevention use of aspirin and statins remained suboptimal in younger patients with premature or
extremely premature ASCVD. Further research into premature ASCVD, clinician and patient
education, and policy implementation are necessary to better comprehend and mitigate the
disparities in medication use and adherence.
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